PIRAMAL PHARMA
Back to All Ratios
|
PIRAMAL PHARMA Last 5 Year Price to Cash Earnings (PCE) History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|
PCE(x) | 16.66 | - | - |
What is the latest Price to Cash Earnings (PCE) ratio of PIRAMAL PHARMA ?
Year | Price to Cash Earnings (PCE) |
---|---|
Mar2023 | 16.66 |
Mar2022 | - |
Mar2021 | - |
How is Price to Cash Earnings (PCE) of PIRAMAL PHARMA Trending?
Years | Price to Cash Earnings (PCE) | % Change | |
---|---|---|---|
Mar2023 | 16.66 | 0 | |
Mar2022 | 0 | 0 | |
Mar2021 | 0 | - |
Other Financial Ratios of PIRAMAL PHARMA
Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER Price/Book Yield EV/Net Sales EV/Core EBITDA EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap |
Compare Price to Cash Earnings (PCE) ratio of peers of PIRAMAL PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
PIRAMAL PHARMA | ₹19,784.0 Cr | 0.4% | 5.4% | 110.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹367,290.0 Cr | -0.9% | 0.9% | 62.6% | Stock Analytics | |
CIPLA | ₹113,357.0 Cr | 3.5% | 4.2% | 51.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹111,134.0 Cr | 12.2% | 18% | 103.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹104,235.0 Cr | 0.8% | 5.6% | 19.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,001.5 Cr | -1% | -2.4% | 28.4% | Stock Analytics |
PIRAMAL PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
PIRAMAL PHARMA | 0.4% |
5.4% |
110.9% |
SENSEX | 1.7% |
1.5% |
18.7% |
You may also like the below Video Courses